Ekso Bionics (NASDAQ:EKSO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report sent to investors on Sunday morning. The firm issued a hold rating on the stock.

EKSO has been the topic of several other research reports. HC Wainwright increased their target price on Ekso Bionics from $9.25 to $10.00 and gave the company a buy rating in a research note on Tuesday, April 30th. Lake Street Capital assumed coverage on shares of Ekso Bionics in a research report on Monday, June 24th. They issued a buy rating and a $2.50 price target on the stock.

Ekso Bionics Trading Up 2.6 %

EKSO opened at $1.38 on Friday. The firm has a 50 day simple moving average of $1.17 and a 200 day simple moving average of $1.55. Ekso Bionics has a fifty-two week low of $0.62 and a fifty-two week high of $3.13. The company has a market cap of $25.07 million, a price-to-earnings ratio of -1.42 and a beta of 1.51. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.81 and a quick ratio of 2.11.

Ekso Bionics (NASDAQ:EKSO) last released its earnings results on Monday, April 29th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04). The business had revenue of $3.76 million for the quarter, compared to analyst estimates of $4.99 million. Ekso Bionics had a negative return on equity of 95.36% and a negative net margin of 79.48%. During the same period in the prior year, the firm posted ($0.33) EPS. On average, sell-side analysts anticipate that Ekso Bionics will post -0.43 earnings per share for the current year.

Institutional Trading of Ekso Bionics

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC lifted its stake in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 596,050 shares of the company’s stock after acquiring an additional 454,892 shares during the period. Kent Lake Capital LLC owned approximately 3.28% of Ekso Bionics worth $811,000 at the end of the most recent quarter. Institutional investors own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.